GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Malaria

Phase 2

Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

CompletedNCT00307021

GlaxoSmithKlineMalaria

Start: 2006-04-07End: 2007-08-22Updated: 2017-04-25

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

CompletedNCT00323622

GlaxoSmithKlineMalaria

Start: 2005-04-30End: 2007-05-31Updated: 2016-12-09

Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children

CompletedNCT00360230

GlaxoSmithKlineMalaria

Start: 2006-08-30End: 2008-05-30Updated: 2018-02-19

Related Papers

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.

2011-04-2741 citations

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).

2011-04-1135 citations

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.

2009-10-2764 citations

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.

2009-10-0265 citations

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

2009-08-0181 citations